Compare Summit Therapeutics Inc (SMMT) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs ProShares Ultra Semiconductors — how do they compare? Summit Therapeutics Inc trades at $14.65 (market cap $10.48B), while ProShares Ultra Semiconductors trades at $90.2. The key difference: ProShares Ultra Semiconductors is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | USD | |
|---|---|---|
Market Cap | $10.48B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $29.32 | $113.53 |
52-Week Low | $13.05 | $39.58 |
Enterprise Value | $9.90B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting ongoing volatility. The company reported a net loss of $1.08 billion for 2025, with negative ROE and ROA, but recent news includes the $105 million divestiture of ridinilazole to sharpen its oncology focus. Technical indicators are bearish, though RSI suggests potential oversold conditions. Analyst consensus remains optimistic with a $15.57 price target and 66.7% buy ratings.
The outlook hinges on clinical success of its lead oncology candidate, ivonescimab, which showed promising survival data. Key risks include high cash burn, binary drug trial outcomes, and shareholder litigation. The stock offers high-risk, high-reward potential for investors betting on pipeline success, but requires careful risk management due to financial losses and volatility.
USD trades at $83.24, up 1.19% with bearish technical signals from moving averages. Key support lies at $80 with resistance at $85. The company announced a $0.14 dividend for H1-2026, payable June 30, 2026. Recent news highlights include coverage of semiconductor sector volatility and earnings from various firms, though specific financials for USD are not detailed in the provided data.
The outlook remains cautious due to bearish technical indicators and limited fundamental data. Investment opportunity hinges on upcoming financial disclosures and sector performance, while risks include market volatility and reliance on broader economic conditions affecting semiconductor and related industries.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
